Reven is pleased to announce the appointment of Daniel Hoffman as Chief Operating Officer, effective immediately. Mr. Hoffman will support co-founders Peter Lange, Michael Volk, and Brian Denomme in executing their vision in bringing the company’s flagship platform drug Rejuveinix (RJX) to market … Read More
News
Latest News
Reven Holdings Announces First Patient Dosed in RPI015 Clinical Trial Evaluating RJX for High-risk COVID-19
Reven today announced that the first patient has been dosed in the Phase I/II trial of RJX in high-risk COVID-19 patients (ClinicalTrials.gov Identifier: NCT04708340 … Read More
Reven Holdings Announces the Launch of Its Translational Oncology Program: Targeting Tumor Microenvironment to Improve Treatment Outcomes in Cancer
Reven has launched its translational oncology program as a new drug discovery and development initiative that is aimed at changing the therapeutic landscape for difficult-to-treat forms of cancer. The overarching goal of this program is to treat cancer patients more effectively by altering the immediate surroundings of their tumor tissue, also known as the tumor microenvironment (TME). … Read More
Reven 2020YE Shareholder Update
We are happy to share the progress of Reven Holdings, Inc. (“Reven”) for the 2020 year. Despite an unprecedented global pandemic, 2020 was another year filled with major milestones for the company … Read More
Reven Pharmaceuticals Reports Positive Results Regarding the Clinical Safety and Preclinical Efficacy of its COVID-19 Drug Candidate Rejuveinix (RJX)
Reven today announced the publication of a peer-reviewed article in the prestigious medical journal, Frontiers in Pharmacology, Section: Respiratory Pharmacology. In this new publication, the Reven Pharmaceuticals team reports positive results regarding the clinical safety and preclinical efficacy … Read More
Reven Pharmaceuticals Reports on the Importance of Micronutrients and Vitamins for COVID-19 in a Prestigious Medical Journal
Reven today announced the provisional acceptance and early online publication of a peer-reviewed article authored by its Chief Medical Officer & Chief Scientific Officer, Fatih Uckun M.D. Ph.D., and his academic collaborators in the medical journal, Frontiers in Nutrition … Read More
Reven Pharmaceuticals Wins FDA Approval of its IND Application for Treatment of COVID-19 With Rejuveinix (RJX)
Reven today announced that the U.S Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application in connection with its lead anti-inflammatory/anti-oxidant investigational drug product Rejuveinix (RJX) as a potential treatment for COVID-19 patients … Read More
Reven Strengthens its Clinical Team with Three New Members
Reven today announced that three new members with extensive experience and knowledge in clinical research and quality assurance have joined its multi-disciplinary team to work on the COVID-19 clinical project … Read More
Reven Selects E-Clinical Services Provider DSG for Clinical Data Management Services
Reven is planning to initiate a randomized, double-blind, placebo-controlled, multi-institutional clinical trial of its lead anti-inflammatory/anti-oxidant investigational drug product Rejuveinix (RJX) in the treatment of COVID-19. … Read More
Reven Selects APCER Life Sciences as Its Service Provider in Pharmacovigilance, Safety Monitoring, Quality Assurance and Regulatory Affairs for Its Upcoming COVID-19 Clinical Trial
Reven today announced that it selected the global specialty drug safety services provider APCER Life Sciences (APCER) as its preferred vendor to provide pharmacovigilance (PVG), safety monitoring, quality assurance and … Read More
US Patent and Trademark Office Allows Reven’s Patent Application to Issue as a New Patent
Reven today announced that it received a formal Notice of Allowance from the US Patent and Trademark Office regarding its patent application entitled: “Compositions and Methods for the Prevention and Treatment of Cardiovascular Disease … Read More
Reven’s Patented, First-in-Class Anti-inflammatory Treatment Platform for Sepsis on Track for Clinical Testing in COVID-19 Patients
Reven had recently submitted a Pre-Investigational New Drug (Pre-IND) application to the U.S. Food and Drug Administration (FDA) to obtain feedback and guidance for its clinical evaluation of the anti-inflammatory/anti-oxidant investigational drug product Rejuveinix (RJX) in the treatment of COVID-19. Reven today announced that FDA has responded favorably to its Pre-IND application … Read More
Reven Publishes New COVID-19 Related Articles Outlining Clinical Impact Potential of Its RJX Platform
Reven today announced the publication of two peer-reviewed expert articles authored by its Chief Medical Officer & Chief Scientific Officer, Fatih Uckun M.D. Ph.D., and other members of the Reven team and their academic collaborators in the medical journal, Clinical Investigation (London) … Read More
Reven Announces the Appointment of Eminent Physician-Scientist Fatih M. Uckun, M.D. Ph.D., Internationally Recognized for his Seminal Contributions to Oncology, Immunology and Immunity, as its Chief Medical Officer and Chief Scientific Officer
In his new position at Reven, Dr. Uckun will provide executive oversight for Reven’s global Research & Development and clinical programs. In addition, Dr. Uckun will contribute medical-scientific leadership and direction for Reven’s basic and translational research activities … Read More
Rejuveinix (RJX) as a drug candidate for patients with systemic inflammatory response syndrome (SIRS): Supportive care considerations for COVID-19, cancer, and sepsis
Sepsis is the consequence of a systemic host inflammatory response to an infection with bacteria, fungi or viruses that is further associated with profound metabolic alterations (1-9). Severe sepsis is frequently associated
with septic shock … Read More